| Identification | |
| Name: | Orlistat |
| Synonyms: | (-)-Tetrahydrolipstatin;Alli;N-Formyl-L-leucine, ester with (3S,4S)-3-hexyl-4-((2S)-2-hydroxytridecyl)-2-oxetanone;Orlistat [USAN:INN];Ro 18-0647/002;Orlipastatum [INN-Latin];L-Leucine, N-formyl-, 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester, (2S-(2alpha(R*),3beta))-;[(2S)-1-[(2S,3S)-3-hexyl-4-oxo-oxetan-2-yl]tridecan-2-yl] 2-formamido-4-methyl-pentanoate;Tetrahydrolipstatin;Xenical;L-Leucine,N-formyl-,(1S)-1-[[(2S,3S)-3- hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester;Taizhou hikong chemical sell orlistat; |
| CAS: | 96829-58-2 |
| Molecular Formula: | C29H53NO5 |
| Molecular Weight: | 495.73482 |
| Molecular Structure: |  |
| Properties | |
| Melting Point: | <50oC |
| Flash Point: | 326.3 oC |
| Boiling Point: | 615.9 oC at 760 mmHg |
| Density: | 0.976 g/cm3 |
| Refractive index: | 1.469 |
| Water Solubility: | DMSO: 19 mg/mL in water |
| Solubility: | DMSO: 19 mg/mL in water |
| Appearance: | White crystalline powder |
| Specification: |
Side effects of Orlistat (CAS NO.96829-58-2): The primary side effects of the drug are gastrointestinal-related, and include steatorrhea (oily, loose stools with excessive flatus due to unabsorbed fats reaching the large intestine), fecal incontinence and frequent or urgent bowel movements. |
| Biological Activity: | Hypolipemic pancreatic, gastric and carboxylester lipase inhibitor. Exhibits no activity at phospholipase A 2 , liver esterase, trypsin and chymotrypsin. Inhibits the thioesterase domain of fatty acid synthase, leading to cell cycle arrest at the G 1 /S boundary in vitro . Prevents the absorption of approximately one third of fat from food and exhibits progastrokinetic, antiobesity and antihypercholesterolemic activity in vivo . |
| Flash Point: | 326.3 oC |
| Color: | white |
| Usage: | An antiobesity agent. A pancreatic lipase inhibitor |
| Safety Data | |
 |
|
